Active Not Recruiting OBSERVATIONAL NCT05029869

Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy Study Description

Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy

Sponsor: University Medical Center Ho Chi Minh City (UMC)

Interventions ctDNA

Updated 8 times since 2021 Last updated: Aug 8, 2025 Started: Oct 4, 2021 Primary completion: Dec 30, 2026 Completion: Dec 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Gastric Cancer and ctDNA and is currently ongoing. University Medical Center Ho Chi Minh City (UMC) leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting

Status: Unknown → Active Not Recruiting
Nov 2024 — Sep 2025 [monthly]

Unknown

Status: Recruiting → Unknown
Sep 2024 — Nov 2024 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
May 2022 — Jul 2024 [monthly]

Recruiting

▶ Show 3 earlier versions

Jan 2022 — May 2022 [monthly]

Recruiting
Dec 2021 — Jan 2022 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Oct 2021 — Dec 2021 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Medical Center Ho Chi Minh City (UMC)

Data source: University Medical Center Ho Chi Minh City (UMC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ho Chi Minh City, Vietnam